[Skip to Content]
[Skip to Content Landing]
Views 301
Citations 0
Comment & Response
March 2015

Treatment of Borderline Elevated Thyrotropin Levels

Author Affiliations
  • 1Manchester Medical Association, Manchester, England
JAMA Intern Med. 2015;175(3):466. doi:10.1001/jamainternmed.2014.7847

To the Editor Over and above the substantial risk of developing a suppressed thyrotropin level following replacement therapy,1 there is a risk that thyroid replacement therapy may precipitate transition to persistent atrial fibrillation (AF), with all its attendant sequelae, when replacement therapy is administered to patients with unrecognized paroxysmal AF (PAF).

First Page Preview View Large
First page PDF preview
First page PDF preview